At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 2,858 enrolled
Drug / intervention
DR-102drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of a Combination Oral Contraceptive Regimen (DR-102) for the Prevention of Pregnancy in Women
Teva Branded Pharmaceutical Products R&D, Inc.·interventional·Posted Aug 9, 2010·Updated Nov 9, 2021
In Brief
A Phase 3 clinical trial evaluating DR-102 for Contraception and Female Contraception. Completed, enrolled 2,858 participants across 62 sites in 2 countries.
Detailed Summary
This is an open-label, single treatment study. All subjects will receive 12 months of oral contraceptive therapy with DR-102. Study participants will receive physical and gynecological exams, including Pap smear. During the study, all participants will be required to complete a daily diary.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsContraception, Female Contraception
CountriesIsrael, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2010
First PostedAug 2010
Primary CompletionJan 2013
TodayJul 2026
First PostedAug 9, 2010
Enrollment StartAug 1, 2010
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 15.9 years ago
Interventions
DR-102drug